The biggest barrier to GLP-1 drugs — the needle — just came down. With oral semaglutide (already available as Rybelsus) gaining broader approval and uptake, millions of people who'd never have accepted a weekly injection now have access to the same active mechanism in pill form. This shift creates a new user profile — and different nutritional needs compared to injectable users.
Key Points
- Oral semaglutide approved — injection barrier removed, market dramatically expands
- GLP-1s reduce appetite 20-30% — protein and micronutrient deficits are common without guidance
- 30-40% of weight lost on GLP-1 can be lean mass without nutritional intervention
- GLP-1 companion supplements: 124% CAGR (NBJ 2026 report)
- New oral user profile: less obese, often active — different nutritional needs than traditional injectable users
The New Oral GLP-1 User Profile
Injectable users (Ozempic, Wegovy) were predominantly people with a BMI over 30 and often comorbidities. Oral semaglutide changes that profile. Without the injection barrier, people with moderate weight excess — BMI 26-30 — and often physically active will access this treatment.
Why this matters nutritionally: someone who works out 3-4 times a week and takes oral semaglutide has higher protein needs, suppressed caloric intake, and real muscle loss risk if they don't proactively adjust nutrition.
The Muscle Loss Problem
Injectable semaglutide clinical trials show that 30-40% of total weight lost can be lean mass (muscle, intracellular water) if protein intake isn't maintained. That's the top nutritional risk of GLP-1s.
With appetite reduced 20-30%, users naturally eat less. But they disproportionately reduce protein-rich foods (meat, eggs, fish) because these foods are more satiating and less appealing during treatment. Result: protein balance goes negative.
Minimum recommendation: maintain protein intake of 1.2 to 1.6g per kg of body weight throughout treatment, even with reduced appetite. For active users, target 1.6-2.0g/kg.
Micronutrient Deficits to Watch
With reduced food volume, micronutrient deficiency risk rises. Long-term GLP-1 use studies identify several common deficiencies:
- Vitamin B12: often carried by animal foods that may decline in consumption
- Iron: especially in women and athletes
- Calcium and Vitamin D: if dairy consumption drops
- Magnesium: frequently deficient in the general population, amplified by caloric reduction
What Coaches and Nutritionists Need to Know
As GLP-1s go mainstream, coaches and nutritionists will see more clients on treatment — often without having been informed of the nutritional implications. Medical prescriptions don't always include dietary follow-up.
Key questions to ask a GLP-1 client:
- Are you able to maintain your protein intake despite reduced appetite?
- Do you have nutritional monitoring from your doctor?
- How has your body composition changed since starting treatment?
This is a real opportunity for fitness and nutrition professionals: accompany GLP-1 clients nutritionally to maximize fat loss while preserving muscle mass. The rise of GLP-1 companion supplements designed to close these nutrition gaps reflects just how concrete and differentiated that value has become.